Non-Current Liabilities
Long-Term Debt
Royalty Pharma Long-Term Debt increased by 0.1% to $8.58B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.6%, from $6.62B to $8.58B. Over 5 years (FY 2020 to FY 2025), Long-Term Debt shows an upward trend with a 8.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ4 2016
Last reportedQ1 2026
How to read this metric
An increase indicates higher leverage and interest expense, while a decrease suggests debt repayment or deleveraging.
Detailed definition
This represents the total value of debt obligations, such as bonds or loans, that are due for repayment beyond the curre...
Peer comparison
Varies significantly by industry; capital-intensive sectors like healthcare often carry higher long-term debt.
Metric ID:
long_term_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.83B | $7.09B | $7.10B | $7.10B | $7.11B | $6.11B | $6.12B | $6.12B | $6.13B | $6.13B | $6.14B | $6.14B | $7.60B | $6.61B | $6.61B | $6.62B | $7.00B | $8.57B | $8.57B | $8.58B |
| QoQ Change | — | +21.7% | +0.1% | +0.1% | +0.1% | -14.0% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +23.8% | -13.0% | +0.1% | +0.1% | +5.8% | +22.3% | +0.1% | +0.1% |
| YoY Change | — | — | — | — | +22.0% | -13.8% | -13.8% | -13.8% | -13.8% | +0.3% | +0.3% | +0.3% | +24.1% | +7.8% | +7.8% | +7.8% | -7.9% | +29.6% | +29.6% | +29.6% |
Range$5.83B – $8.58B
CAGR+8.5%
Avg YoY Growth+6.0%
Median YoY Growth+4.0%
Current Streak6 quarters growth
Long-Term Debt at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's long-term debt?
- Royalty Pharma (RPRX) reported long-term debt of $8.58B in Q1 2026.
- How has Royalty Pharma's long-term debt changed year-over-year?
- Royalty Pharma's long-term debt increased by 29.6% year-over-year, from $6.62B to $8.58B.
- What is the long-term trend for Royalty Pharma's long-term debt?
- Over 5 years (2020 to 2025), Royalty Pharma's long-term debt has grown at a 8.1% compound annual growth rate (CAGR), from $5.82B to $8.57B.
- What does long-term debt mean?
- The total amount of debt that is not due for repayment within the next year.